Pricing Log in Create free account
Monday 9 November 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS

Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue
−0.28%
EPS
−157.5%
Free cash flow
+38.8%
Total debt
−18.1%

Quarter to September 2026, against a year earlier

20.45 0.54 +2.71%
Market cap
$22.8B
P/E
n/m
Fwd P/E
n/m
Dividend yield
2.35%
F-score
4/9
ROIC
−0.01%
Net debt / EBITDA
4.9×
Dividend safety
37/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Viatris Inc. (VTRS) revenue by segment, product and region

Annual Quarterly
Download Excel — free account

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Developed Markets Segment 8,514 59.54%
Greater China 2,333 16.31%
Emerging Markets Segment 2,210 15.46%
Japan, Australia and New Zealand Segment 1,194 8.35%
Gross margin 35.06%
Operating margin (18.62%)
Pre-tax margin (25.63%)

Revenue by segment $m

Line FY2025 FY2024 FY2023 FY2022
Developed Markets Segment 8,514 8,929 9,252 9,769
Greater China 2,333 2,167 2,160 2,201
Emerging Markets Segment 2,210 2,251 2,552 2,616
Japan, Australia and New Zealand Segment 1,194 1,346 1,425 1,632
Revenue 14,250 14,693 15,388 16,218

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.